InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Why Monsanto raises important issues for biotech industry

James Nurton, London


It will remain difficult to get protection for recombinant products purely on the basis of a patent to the gene, following the Court of Justice’s recent decision in the Monsanto case – according to the UK’s BioIndustry Association

In a statement on the decision, which is the first time the EU’s Court of Justice has interpreted an issue of substantive patent law, John Murphy, chair of the BIA’s IP Advisory Committee said the ruling raises "some important issues...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

Supplements

Most read articles